KALA BIO Inc. Common Stock (KALA)
Stock · NASDAQ · Health Care
$0.19as of 10/16/2026
Price chart
Active signals
KALA Signal Track Record
How signals performed across all stocks →What KALA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 22 | -12.5% | 27% | September 28, 2026 |
| Bollinger Band Breakout | 18 | -13.4% | 39% | August 12, 2026 |
| Volume Spike | 12 | -40.3% | 0% | September 29, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -6.2% | 45% | July 11, 2025 |
| Any 20-session window (baseline) | -8.2% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KALA
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation envir…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- www.kalarx.com/
Fundamentals
- 1-day range
- $0.1146$0.2646
- Market cap
- $14.25M
- P/E (trailing)
- —
- P/E (forward)
- -0.03
- EPS (trailing)
- $-72.45
- Dividend yield
- —
- Beta
- -2.51
- Avg. volume
- 1.46M
How KALA BIO Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 3, 2023 · via SEC EDGAR / Finnhub
KALA BIO Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KALAKALA BIO Inc. Common Stock$0.19▼ 1.04%Market cap $14.25MP/E —$0.2593$95.5
- COCPCocrystal Pharma Inc. Common Stock$1.02▼ 0.97%Market cap $14.20MP/E —$0.76$2.03
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
- TPSTTempest Therapeutics Inc. Common Stock$0.624▼ 1.73%Market cap $14.42MP/E —$0.6801$12.23
- PTNPalatin Technologies Inc. Common Stock$6.02▼ 7.24%Market cap $14.00MP/E 92.55$5.61$31
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
- KTTAPasithea Therapeutics Corp. Common Stock$0.42▲ 2.44%Market cap $14.82MP/E —$0.281$2.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KALA KALA BIO Inc. Common Stock | $14.25M | — | $0.19 | ▼ 1.04% | $0.2593$95.5 |
| COCP Cocrystal Pharma Inc. Common Stock | $14.20M | — | $1.02 | ▼ 0.97% | $0.76$2.03 |
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
| TPST Tempest Therapeutics Inc. Common Stock | $14.42M | — | $0.624 | ▼ 1.73% | $0.6801$12.23 |
| PTN Palatin Technologies Inc. Common Stock | $14.00M | 92.55 | $6.02 | ▼ 7.24% | $5.61$31 |
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
| KTTA Pasithea Therapeutics Corp. Common Stock | $14.82M | — | $0.42 | ▲ 2.44% | $0.281$2.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 10/1/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/30/2026
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketBenzinga · 9/30/2026
- KALA Bio (KALA) Shares Soar 57% After Hours: Here's WhyBenzinga · 9/30/2026
- KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since InceptionYahoo · 9/29/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/29/2026
- KALA Bio Inks Letter Of Intent To Acquire U.S.-Based Management Services Firm For ~$15MBenzinga · 9/29/2026
- Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsYahoo · 9/24/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.